The FDA Race And Ethnicity Diversity Plan: How To Get Researchers Prepared

Following its inclusion in the 2023 omnibus spending bill and subsequent signing into U.S. law, the DEPICT Act has ushered in a significant shift in American clinical research. This legislation mandates compliance with the FDA's diversity plan, aiming to promote greater racial and ethnic inclusiveness within clinical trials.

In this article, the authors delve into the key facets of clinical research that are directly influenced by the DEPICT Act, specifically outlining the responsibilities that now fall upon researchers regarding ensuring compliance that meets the new regulations. In addition, lingering questions and challenges that the law raises in the pursuit of more equitable and representative clinical research are also addressed.

Access the article below to better understand how this legislative change not only underscores the importance of diversity in research but also sets the stage for a more inclusive and comprehensive approach to healthcare development in the United States.